» Articles » PMID: 27098303

In Vivo Monitoring of CD44+ Cancer Stem-like Cells by γ-irradiation in Breast Cancer

Overview
Journal Int J Oncol
Specialty Oncology
Date 2016 Apr 22
PMID 27098303
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

There is increasing evidence that cancer contains cancer stem cells (CSCs) that are capable of regenerating a tumor following chemotherapy or radiotherapy. CD44 and CD133 are used to identify CSCs. This study investigated non-invasive in vivo monitoring of CD44-positive cancer stem-like cells in breast cancer by γ-irradiation using molecular image by fusing the firefly luciferase (fLuc) gene with the CD44 promoter. We generated a breast cancer cell line stably expressing fLuc gene by use of recombinant lentiviral vector controlled by CD44 promoter (MCF7-CL). Irradiated MCF7-CL spheres showed upregulated expression of CD44 and CD133, by immunofluorescence and flow cytometry. Also, gene expression levels of CSCs markers in irradiated spheres were clearly increased. CD44+ CSCs increased fLuc expression and tumor growth in vivo and in vitro. When MCF7-CL was treated with siCD44 and irradiated, CD44 expression was inhibited and cell survival ratio was decreased. MCF7-CL subsets were injected into the mice and irradiated by using a cobalt-60 source. Then, in vivo monitoring was performed to observe the bioluminescence imaging (BLI). When breast cancer was irradiated, relative BLI signal was increased, but tumor volume was decreased compared to non-irradiated tumor. These results indicate that increased CD44 expression, caused by general feature of CSCs by irradiation and sphere formation, can be monitored by using bioluminescence imaging. This system could be useful to evaluate CD44- expressed CSCs in breast cancer by BLI in vivo as well as in vitro for radiotherapy.

Citing Articles

The Concept of Cancer Stem Cells: Elaborating on ALDH1B1 as an Emerging Marker of Cancer Progression.

Tsochantaridis I, Roupas A, Mohlin S, Pappa A, Voulgaridou G Life (Basel). 2023; 13(1).

PMID: 36676146 PMC: 9863106. DOI: 10.3390/life13010197.


CSC Radioresistance: A Therapeutic Challenge to Improve Radiotherapy Effectiveness in Cancer.

Olivares-Urbano M, Grinan-Lison C, Marchal J, Isabel Nunez M Cells. 2020; 9(7).

PMID: 32660072 PMC: 7407195. DOI: 10.3390/cells9071651.


Different Proteins Regulated Apoptosis, Proliferation and Metastasis of Lung Adenocarcinoma After Radiotherapy at Different Time.

Dai P, Du X, Hou Y, Li L, Xia Y, Wang L Cancer Manag Res. 2020; 12:2437-2447.

PMID: 32308480 PMC: 7135201. DOI: 10.2147/CMAR.S219967.


Biological Functions and Identification of Novel Biomarker Expressed on the Surface of Breast Cancer-Derived Cancer Stem Cells via Proteomic Analysis.

Koh E, You J, Jung S, Kim P Mol Cells. 2020; 43(4):384-396.

PMID: 32235022 PMC: 7191048. DOI: 10.14348/molcells.2020.2230.


Evaluation of the correlativity of gender determining region Y-box 4, N-cadherin, CD44 and E-cadherin expression in the prognosis of esophageal squamous cell carcinoma.

Qin Y, Zhao W, Cheng L, Gao J, Bian Z, Wu S Int J Clin Exp Pathol. 2020; 12(5):1745-1756.

PMID: 31933993 PMC: 6947138.


References
1.
Herring P . Species abundance, sexual encounter and bioluminescent signalling in the deep sea. Philos Trans R Soc Lond B Biol Sci. 2000; 355(1401):1273-6. PMC: 1692854. DOI: 10.1098/rstb.2000.0682. View

2.
Gomez-Casal R, Bhattacharya C, Ganesh N, Bailey L, Basse P, Gibson M . Non-small cell lung cancer cells survived ionizing radiation treatment display cancer stem cell and epithelial-mesenchymal transition phenotypes. Mol Cancer. 2013; 12(1):94. PMC: 3751356. DOI: 10.1186/1476-4598-12-94. View

3.
Contag C, Bachmann M . Advances in in vivo bioluminescence imaging of gene expression. Annu Rev Biomed Eng. 2002; 4:235-60. DOI: 10.1146/annurev.bioeng.4.111901.093336. View

4.
Contag C, Ross B . It's not just about anatomy: in vivo bioluminescence imaging as an eyepiece into biology. J Magn Reson Imaging. 2002; 16(4):378-87. DOI: 10.1002/jmri.10178. View

5.
Naor D, Nedvetzki S, Golan I, Melnik L, Faitelson Y . CD44 in cancer. Crit Rev Clin Lab Sci. 2002; 39(6):527-79. DOI: 10.1080/10408360290795574. View